- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Proto Script Pharmaceutical Completes Share Structure Improvements
Proto Script Pharmaceutical (OTC PINK: PSCR) announced the completion of an exchange of 295,000,000 common stock shares for 1,500,000 newly issued multiple-voting convertible preferred series A shares.
Proto Script Pharmaceutical (OTC PINK: PSCR) announced the completion of an exchange of 295,000,000 common stock shares for 1,500,000 newly issued multiple-voting convertible preferred series A shares.
As quoted in the press release:
As result of the definitive Share Exchange Agreement between the Company and Michelle Rico, the Company’s president and PSP Homecare founder, 295,000,000 shares of restricted common stock held by Michelle Rico were exchanged for 1,500,000 newly issued multiple-voting convertible Preferred Series A shares. Preferred Series A shares are convertible into twenty (20) common shares each and are entitled to 200 votes per share. Common shares issuable via Preferred Series A conversion remain restricted. To date, Michelle Rico has sold no shares of PSCR common or preferred stock.
Following the share exchange, as of Feb. 23, 2017, there are 49,139,998 shares of PSCR common stock and 1,500,000 shares of Preferred Series A stock outstanding. This represents an 85% reduction in the number of shares of PSCR common stock outstanding compared to prior to the share exchange. If converted, on a fully diluted basis, the 1,500,000 Preferred Series A shares would represent an additional 30,000,000 PSCR common shares (20 for 1 conversion ratio) bringing the total outstanding common shares to 79,139,998. This would still represent a significant 76% reduction in the number of PSCR common shares outstanding compared to prior to the share exchange.
The current number of outstanding PSCR common shares (49,139,998) has been verified by the Company’s transfer agent, as indicted in the Company’s OTC Markets Profile at www.otcmarkets.com/stock/PSCR/profile.
Additional information regarding PSP Homecare can be found at www.psphomecare.com.
About Proto Script Pharmaceutical Corp.
Proto Script Pharmaceutical Corp. dba PSP Homecare provides a comprehensive collection of durable medical equipment (DME) like canes, crutches, walkers, commodes, patient lifts, hospital beds, orthotics (braces), wheelchairs, scooters, power wheelchairs, rehabilitation equipment, and accessories. Currently serving California and Nevada, PSP Homecare has specialized in the repair of power wheelchairs and the sale of orthotics since 2011. The Company deals with a growing list of federal, state and private insurance providers such as Medicare, Medi-Cal, Nevada Care and Blue Cross among several others.
Proto Script Pharmaceutical Corp. files reports with the Securities & Exchange Commission on EDGAR and anticipates continuing to file such reports. The Company’s filings can be viewed at www.sec.gov.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.